Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Enzalutamide (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Jun 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
- 24 Jun 2024 Planned primary completion date changed from 1 May 2024 to 1 May 2025.
- 26 Apr 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.